Chardan Capital Expects Lower Earnings for Dyne Therapeutics

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Research analysts at Chardan Capital decreased their FY2024 earnings estimates for Dyne Therapeutics in a note issued to investors on Wednesday, November 13th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings of ($3.14) per share for the year, down from their prior estimate of ($2.75). Chardan Capital has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.39) per share. Chardan Capital also issued estimates for Dyne Therapeutics’ FY2025 earnings at ($2.73) EPS.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25).

A number of other brokerages have also issued reports on DYN. Piper Sandler restated an “overweight” rating and issued a $53.00 target price on shares of Dyne Therapeutics in a research note on Monday, September 23rd. Oppenheimer reiterated an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Stifel Nicolaus upped their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. Morgan Stanley raised their target price on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $43.00 to $35.00 in a report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $51.40.

Dyne Therapeutics Stock Down 6.3 %

DYN stock opened at $28.39 on Monday. The firm has a 50 day moving average of $32.48 and a 200 day moving average of $35.24. The stock has a market capitalization of $2.89 billion, a PE ratio of -7.97 and a beta of 1.10. Dyne Therapeutics has a 52 week low of $9.76 and a 52 week high of $47.45.

Insider Activity at Dyne Therapeutics

In other news, COO Susanna Gatti High sold 8,976 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the transaction, the chief operating officer now directly owns 131,636 shares of the company’s stock, valued at $4,529,594.76. This represents a 6.38 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO John Cox purchased 32,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was bought at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the purchase, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. This trade represents a -133.33 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 158,975 shares of company stock worth $5,693,789. 20.77% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC raised its holdings in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after acquiring an additional 669 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Dyne Therapeutics during the 3rd quarter worth $34,000. Point72 DIFC Ltd acquired a new stake in Dyne Therapeutics during the 3rd quarter worth $36,000. US Bancorp DE grew its holdings in shares of Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after buying an additional 1,212 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new stake in shares of Dyne Therapeutics in the third quarter valued at about $62,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.